Search

Your search keyword '"Wang, Tsung-Jen"' showing total 209 results
Start Over Author "Wang, Tsung-Jen"
209 results on '"Wang, Tsung-Jen"'

7. One-year experience with latanoprostene bunod ophthalmic solution 0.024% in clinical practice: A retrospective observational study.

Author

Hsueh, Chun-Mei, Tsai, Chen-Hsin, Huang, Jou-Chen, Lee, Si-Huei, Wang, Tsung-Jen, and Guo, Siao-Pei

Subjects
OPEN-angle glaucoma, VISUAL fields, NERVE fibers, OPHTHALMIC drugs, SUBGROUP analysis (Experimental design)
Abstract

Purpose: We evaluated the IOP-lowering efficacy and safety of latanoprostene bunod (LBN) ophthalmic solution 0.024% (Vyzulta®), the first topical nitric oxide-donating prostaglandin analog (PGA), in clinical practice. Materials and methods: A retrospective medical chart review from July 2021 to July 2023 of patients with open-angle glaucoma receiving LBN with at least 1 year follow–up was conducted. All included patients received LBN 0.024% as a replacement for a PGA, with examinations at 1-, 3-, 6-and 12-months follow-up. Main outcome measures were IOP, retinal nerve fiber layer thickness, visual fields before/after LBN use and adverse effects. Subgroup analysis with glaucoma types and PGA use were performed for additional IOP reduction after LBN use. Results: Among 78 included patients, 47 patients (81 eyes), 60% with open-angle glaucoma (OAG) remained on LBN throughout 12-month follow-up. Baseline IOP was 18.2±4.2 mm Hg, and Prostaglandin analog (PGA)-IOP was 14.4 ± 3.0 mm Hg (21% mean IOP reduction). After switched to LBN, mean additional IOP reduction was 1.0 mm Hg at month 1, and the greatest reduction was 1.6 mm Hg (8.8% additional mean IOP reduction) at month 12 (P<0.0001). Subgroup analysis (NTG, 73%) showed that mean additional IOP reduction at month 12 was 1.3±2.0 mm Hg in NTG group and 2.1±3.2 mm Hg in POAG group (7.7% vs. 8.7% additional IOP reduction rates, P = 0.23). Subgroup analysis of PGA use at month 12 was 1.8±2.3 mm Hg in tafluoprost group and 0.5±1.7 mm Hg in travoprost group (9.5% vs.2.6% additional IOP reduction rates, P = 0.02). Tolerable ocular adverse effects included irritation (n = 16, 19.8%), mild conjunctival hyperemia (n = 11, 13.6%), dark circles (n = 4, 4.9%) and blurred vision (n = 2, 2.5%). There were no significant visual field and retinal nerve fiber layer thickness changes after 12 months of treatment with LBN 0.024%. Conclusions: Although high intolerable adverse effects including conjunctival hyperemia and eye irritation happened in the first month, remaining sixty percent of patients exhibited statistically significant additional IOP reductions in the replacement of other PGAs during 12 months of clinical use of LBN 0.024%. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. Metastatic choroidal tumors in Taiwan: an 11-year experience

Author

Wang, Tsung-Jen, Yang, Chung-May, Ho, Tzyy-Chang, Huang, Jen-Shang, Lin, Chang-Pin, Yang, Chang-Hao, Chen, Muh-Shy, and Lin, Luke Long-Kuang

Subjects
Choroid -- Diseases, Eye cancer -- Genetic aspects, Metastasis -- Research, Oncology, Experimental -- Reports, Cancer -- Research, Cancer -- Reports, Health
Published
2005

38. Novel chitosan-polycaprolactone blends as potential scaffold and carrier for corneal endothelial transplantation

Author

Wang, Tsung-Jen, Wang, I-Jong, Lu, Jui-Nan, and Young, Tai-Horng

Subjects
Chitosan, Extracellular Matrix Proteins, Tissue Engineering, Tissue Scaffolds, Polyesters, Endothelium, Corneal, technology, industry, and agriculture, Endothelial Cells, Membrane Proteins, Biocompatible Materials, Membranes, Artificial, macromolecular substances, musculoskeletal system, equipment and supplies, Cornea, Corneal Transplantation, Cell Adhesion, Animals, Humans, Cattle, Cells, Cultured, Research Article, Cell Proliferation
Abstract

Purpose The aim of this prospective study was to evaluate whether blending two kinds of biomaterials, chitosan and polycaprolactone (PCL), can be used as scaffold and carrier for growth and differentiation of corneal endothelial cells (CECs). Methods A transparent, biocompatible carrier with cultured CECs on scaffold would be a perfect replacement graft. In the initial part of experiment, for essential and biocompatible test, chitosan and PCL were evaluated respectively and blended in various proportions by coating. In the later part of this study, for evaluation of potential application, homogenous solutions of 25%, 50%, and 75% PCL compositions were attempted to structure blend membranes. Results Chitosan, PCL 25, PCL 50, and PCL 75 blends could maintain transparency of culturing substrata. BCECs were found to be reached confluence successfully after 7 days on PCL 25, PCL 50, and PCL 75. The expression of tight junction and extracellular matrix protein were observed as well. Alternatively, only PCL 25 could make blend membrane with enough strength during preparation for carrier in culture. On this blend membrane, the growth pattern and phenotype of BCECs could be observed well. Conclusions A ratio of 75:25 (chitosan:PCL) blends showed enough mechanical properties as well as suitable support for cellular activity in cultivating BCECs. Thus, a novel methodology of biodegradable carrier from chitosan and PCL has potential to be a good replacement scaffold for raising CECs for clinical transplantation.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results